Klebsiella Testing MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy TechnologyBy End UserBy Sample Type

Klebsiella testing refers to the diagnostic products and services used to detect and characterize Klebsiella pneumoniae and related Klebsiella species in clinical and research specimens, spanning laboratory-based culture and biochemical identification, molecular and immunoassay-based detection, and complementary imaging used to support a clinical diagnosis. These tests are used across hospital and reference laboratories, diagnostic testing centers, and academic and research institutes to confirm infection, guide antibiotic selection, and track antimicrobial resistance. Buyers include laboratory directors, hospital procurement teams, and public health agencies responsible for infection surveillance and stewardship programs.

Between 2025 and 2034 the global klebsiella testing market moves from USD 270 million to USD 731 million, compounding at 11.68% a year. Fifteen years are covered in all, taking in USD 128 million in 2020, USD 231 million in 2024, USD 302 million in 2026 and USD 473 million in 2030.

78% of 2025 revenue sits in Laboratory Test, worth USD 210.6 million and rising to USD 540.94 million at 74% by 2034, the largest type line in both years. Growth is fastest in Other at 15.71% and slowest in Imaging Test at 10.23%. The lines gaining share are Other. Laboratory Test and Imaging Test lose share without losing revenue.

By application, Laboratory Test accounts for 78% of 2025 revenue at USD 210.6 million, reaching USD 540.94 million and 74% by 2034. Other grows faster at 15.81% against 11.06%, moving from 13% of revenue to 18% by 2034. This axis divides the same revenue as the type split rather than adding to it, so the two are read together rather than summed.

Geographically, 38% of 2025 revenue sits in North America (USD 102.6 million rising to USD 248.54 million) ahead of Europe at 27% and USD 72.9 million. Middle East and Africa is smallest, at 5%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, which is what makes the regional split worth reading rather than assuming.

Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies rather than a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global klebsiella testing market moves from USD 128 million in 2020 to USD 270 million in 2025 and USD 731 million by 2034, the forecast period compounding at 11.68% a year.
• The largest line by type is Laboratory Test, worth USD 210.6 million and 78% of revenue in 2025, rising to USD 540.94 million and 74% by 2034.
• At 15.71%, Other grows faster than any other type line, moving from USD 35.1 million and 13% of revenue in 2025 to USD 131.58 million and 18% in 2034.
• The bull case puts 2034 revenue at USD 818.72 million and the bear case at USD 657.9 million, either side of the USD 731 million base case, each with its own stated assumption in the full report.
• North America holds 38% of global revenue in 2025 at USD 102.6 million, the largest of the five regions tracked, and reaches USD 248.54 million by 2034.
• 85% of North America's base-year revenue comes from the United States alone: USD 87.21 million in 2025, rising to USD 211.26 million by 2034, which is why it is that region's worked example.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

The global klebsiella testing market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 11.68% rate carrying the total.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.

Other grows faster than Imaging Test. The widest spread on the type axis is between Other at 15.71% and Imaging Test at 10.23%. Other takes its share of revenue from 13% to 18% while Imaging Test gives up ground, from 9% to 8%. The revenue figures behind that are USD 35.1 million to USD 131.58 million and USD 24.3 million to USD 58.48 million. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 24% of revenue in 2025 to 30% in 2034, worth USD 64.8 million rising to USD 219.3 million; Latin America moves from 6% of revenue in 2025 to 6.5% in 2034, worth USD 16.2 million rising to USD 47.52 million; Middle East and Africa moves from 5% of revenue in 2025 to 5.5% in 2034, worth USD 13.5 million rising to USD 40.21 million. Against that, North America at 38% moving to 34%, Europe at 27% moving to 24%, a fall in share, not in revenue. Revenue added in this market is therefore concentrating geographically rather than spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

Growth compounds at 11.68% without a step change. Year by year the total runs USD 128 million in 2020, USD 231 million in 2024, USD 270 million in 2025, USD 302 million in 2026, USD 473 million in 2030 and USD 731 million in 2034. The forecast rate of 11.68% sits against 16.11% over the historical period, so the projection extends an observed trend instead of proposing a new one. The risk in the number sits in the mix assumptions rather than in whether the market grows at all, which is where the type and regional sections come in.

Growth is concentrated in Other

The 11.68% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

What holds the forecast back

What the bull case turns on

Revenue is concentrated in Laboratory Test

USD 102.6 million of 2025 revenue is generated in North America, 38% of the global klebsiella testing market on the way to USD 248.54 million by 2034. It is a dominant region on this axis, first by revenue throughout the period.

Its share moves to 34% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

Within the region the type split tracks the global one; 78% of 2025 revenue in Laboratory Test, fastest growth of 15.71% in Other. Per-axis and per-country detail for North America sits in the full report.

USD 87.21 million of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 211.26 million by 2034. Carrying 85% of the region in the base year, it sets North America's direction rather than contributing to it. Regional revenue of USD 102.6 million in 2025 and USD 248.54 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

the United States buys along the same lines as the market globally; Laboratory Test first at 78% of 2025 revenue and 74% in 2034, Other fastest at 15.71% on a share moving from 13% to 18%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for the United States is reported separately in the full report.

FDA regulates Klebsiella testing products as in vitro diagnostic devices under the medical device framework, with classification determining the applicable premarket pathway — devices for detecting Klebsiella species and related antimicrobial resistance markers are typically reviewed for substantial equivalence to a legally marketed predicate through the premarket notification pathway, or in select cases via direct authorization for novel diagnostics. Clinical Laboratory Improvement Amendments oversight also governs where and how such assays may be run, including waived, moderate, and high-complexity categories. Suppliers must demonstrate analytical and clinical performance, maintain quality system compliance, and follow labeling requirements specifying intended use, limitations, and interpretation criteria for laboratory and clinician use.

Competition in the United States runs between the suppliers this study tracks: Charles River Laboratories, HiMedia Laboratories, Biomed Diagnostics, Abcam, EastCoast Bio, Others, bioMerieux, Becton, Dickinson and Company, Bruker Corporation, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Hardy Diagnostics and Liofilchem. Volume sits in Laboratory Test at 78% of 2025 revenue; movement sits in Other at 15.71% growth. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 15.39 million in 2025, rising to USD 37.28 million by 2034; 5.7% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 27% of global revenue puts 2025 at USD 72.9 million and reaches USD 175.44 million by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share settles at 24% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the type split tracks the global one; 78% of 2025 revenue in Laboratory Test, fastest growth of 15.71% in Other. Europe is reported axis by axis and country by country in the full study.

The largest single market in Europe is Germany, at USD 21.87 million in 2025 and USD 52.63 million in 2034. 30% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 72.9 million in 2025 and USD 175.44 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Germany buys along the same lines as the market globally; Laboratory Test first at 78% of 2025 revenue and 74% in 2034, Other fastest at 15.71% on a share moving from 13% to 18%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Germany by type separately.

Within the European Union framework, Klebsiella testing products fall under the EU In Vitro Diagnostic Regulation, administered in Germany through the national competent authority alongside independent notified bodies for higher-risk assay classes. Manufacturers must classify their tests according to risk-based rules, undergo conformity assessment appropriate to that class, and affix CE marking before placing devices on the market. Performance evaluation, technical documentation, and a quality management system aligned with recognized international standards for in vitro diagnostics are mandatory. Labelling must state intended purpose, sample type, and performance characteristics, and post-market surveillance obligations continue once the product is in clinical use across German laboratories.

Competition in Germany runs between the suppliers this study tracks: Charles River Laboratories, HiMedia Laboratories, Biomed Diagnostics, Abcam, EastCoast Bio, Others, bioMerieux, Becton, Dickinson and Company, Bruker Corporation, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Hardy Diagnostics and Liofilchem. Two different problems sit on the same axis: holding Laboratory Test at 78% of 2025 revenue, and taking Other while it grows at 15.71%.

6.48% of global revenue is generated in the United Kingdom; USD 17.5 million in 2025, reaching USD 42.11 million in 2034, and 24% of Europe.

Within Europe, France accounts for 18% of regional revenue and 4.86% of the global total, worth USD 13.12 million in 2025 and USD 31.58 million by 2034.

In Asia Pacific, 24% of global revenue puts 2025 at USD 64.8 million with USD 219.3 million projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

30% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 11.68%; the revenue added here is disproportionate to where the region started.

The type mix reported at global level applies here, with Laboratory Test the largest line at 78% of 2025 revenue and Other the fastest-growing at 15.71%. Per-axis and per-country detail for Asia Pacific sits in the full report.

34% of Asia Pacific's base-year revenue comes from China; USD 22.03 million, rising to USD 65.79 million by 2034. 34% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 64.8 million in 2025 and USD 219.3 million in 2034, it is the country the full report breaks out in detail.

Demand in China follows the type mix reported at global level: Laboratory Test is the largest line at 78% of 2025 revenue, moving to 74% by 2034, while Other grows fastest at 15.71% and takes its share from 13% to 18%. With 34% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. China carries its own type breakdown in the full report.

In China, Klebsiella testing products are regulated as in vitro diagnostic reagents by the National Medical Products Administration, which requires registration prior to marketing based on a risk-based classification system. Higher-risk assays intended for detecting pathogenic bacteria and resistance markers generally require more extensive clinical evaluation and registration review, while lower-risk reagents follow a simpler filing route. Suppliers must submit technical and clinical data demonstrating analytical performance, comply with national standards governing reagent manufacturing and quality control, and ensure Chinese-language labelling that accurately states intended use and handling instructions. Local manufacturing or an authorized in-country agent is typically required for imported diagnostic products.

Charles River Laboratories, HiMedia Laboratories, Biomed Diagnostics, Abcam, EastCoast Bio, Others, bioMerieux, Becton, Dickinson and Company, Bruker Corporation, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Hardy Diagnostics and Liofilchem are the suppliers covered in China. Volume sits in Laboratory Test at 78% of 2025 revenue; movement sits in Other at 15.71% growth.

5.76% of global revenue is generated in India; USD 15.55 million in 2025, reaching USD 61.4 million in 2034, and 24% of Asia Pacific.

Within Asia Pacific, Japan accounts for 18% of regional revenue and 4.32% of the global total, worth USD 11.66 million in 2025 and USD 32.9 million by 2034.

USD 16.2 million of 2025 revenue is generated in Latin America, 6% of the global klebsiella testing market with USD 47.52 million projected for 2034. Among the five regions it ranks fourth by revenue in both years.

Share climbs to 6.5% by 2034, so the region grows faster than the market's 11.68% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Laboratory Test largest at 78% of 2025 revenue, Other fastest at 15.71%. Latin America is reported axis by axis and country by country in the full study.

52% of Latin America's base-year revenue comes from Brazil; USD 8.42 million, rising to USD 24.71 million by 2034. Its 52% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Against regional totals of USD 16.2 million in 2025 and USD 47.52 million in 2034, it is the country the full report breaks out in detail.

The type pattern in Brazil is the global one: 78% of 2025 revenue in Laboratory Test, 74% by 2034, against 15.71% growth in Other taking it from 13% to 18%. With 52% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Brazil is reported separately in the full report.

In Brazil, Klebsiella testing products are regulated by the Agência Nacional de Vigilância Sanitária, which oversees in vitro diagnostic products under a risk-based classification and registration regime. Manufacturers and importers must obtain product registration before marketing, demonstrating conformity with applicable technical standards covering analytical performance, manufacturing quality, and safety. Facilities are also subject to good manufacturing practice certification requirements. Labelling must be in Portuguese and clearly state intended use, storage conditions, and interpretation guidance for laboratory personnel. Ongoing pharmacovigilance-style monitoring, referred to as technovigilance for medical products, obliges suppliers to report adverse events or performance failures once the diagnostic is in routine clinical use.

The suppliers tracked in this study (Charles River Laboratories, HiMedia Laboratories, Biomed Diagnostics, Abcam, EastCoast Bio, Others, bioMerieux, Becton, Dickinson and Company, Bruker Corporation, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Hardy Diagnostics and Liofilchem) compete in Brazil across the type lines above. The commercially relevant division is 78% of 2025 revenue in Laboratory Test, where the volume is, against 15.71% growth in Other, where share moves.

Within Latin America, Mexico accounts for 30% of regional revenue and 1.8% of the global total, worth USD 4.86 million in 2025 and USD 14.26 million by 2034.

In Middle East and Africa, 5% of global revenue puts 2025 at USD 13.5 million with USD 40.21 million projected for 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

5.5% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 11.68%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the type split tracks the global one; 78% of 2025 revenue in Laboratory Test, fastest growth of 15.71% in Other. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

USD 3.78 million of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 11.26 million by 2034. Its 28% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. The region itself runs USD 13.5 million to USD 40.21 million over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Saudi Arabia follows the type mix reported at global level: Laboratory Test is the largest line at 78% of 2025 revenue, moving to 74% by 2034, while Other grows fastest at 15.71% and takes its share from 13% to 18%. Because the country carries 28% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Saudi Arabia carries its own type breakdown in the full report.

In Saudi Arabia, Klebsiella testing products are regulated by the Saudi Food and Drug Authority, which governs in vitro diagnostic devices through a national medical device registration system aligned in large part with international regulatory conventions. Suppliers must register both the manufacturing establishment and the device itself, classify the product according to risk, and demonstrate conformity with recognized international standards for diagnostic performance and quality management. Labelling must appear in Arabic alongside English, stating intended use and handling instructions. Authorization typically depends on prior approval or marketing history in a reference regulatory jurisdiction, and importers must maintain a licensed local presence to distribute the product within the Kingdom.

In Saudi Arabia the field is Charles River Laboratories, HiMedia Laboratories, Biomed Diagnostics, Abcam, EastCoast Bio, Others, bioMerieux, Becton, Dickinson and Company, Bruker Corporation, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Hardy Diagnostics and Liofilchem. Volume sits in Laboratory Test at 78% of 2025 revenue; movement sits in Other at 15.71% growth.

1.1% of global revenue is generated in South Africa; USD 2.97 million in 2025, reaching USD 8.85 million in 2034, and 22% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, technology, end user, sample type, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.